615 related articles for article (PubMed ID: 18977528)
1. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines.
García MG; Alaniz L; Lopes EC; Blanco G; Hajos SE; Alvarez E
Leuk Res; 2005 Dec; 29(12):1425-34. PubMed ID: 15982733
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
4. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
5. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.
Yeheskely-Hayon D; Regev R; Eytan GD; Dann EJ
Leuk Res; 2005 Jul; 29(7):793-802. PubMed ID: 15927675
[TBL] [Abstract][Full Text] [Related]
8. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
[TBL] [Abstract][Full Text] [Related]
9. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
[TBL] [Abstract][Full Text] [Related]
10. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
[TBL] [Abstract][Full Text] [Related]
12. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
13. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Silvestri R; Marfè G; Artico M; La Regina G; Lavecchia A; Novellino E; Morgante E; Di Stefano C; Catalano G; Filomeni G; Abruzzese E; Ciriolo MR; Russo MA; Amadori S; Cirilli R; La Torre F; Sinibaldi Salimei P
J Med Chem; 2006 Sep; 49(19):5840-4. PubMed ID: 16970408
[TBL] [Abstract][Full Text] [Related]
15. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
16. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH
J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822
[TBL] [Abstract][Full Text] [Related]
17. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Silva KL; de Souza PS; Nestal de Moraes G; Moellmann-Coelho A; Vasconcelos Fda C; Maia RC
Leuk Res; 2013 Oct; 37(10):1350-8. PubMed ID: 23891189
[TBL] [Abstract][Full Text] [Related]
18. Ionic currents in multidrug resistant K562 human leukemic cells.
Assef YA; Cavarra SM; Damiano AE; Ibarra C; Kotsias BA
Leuk Res; 2005 Sep; 29(9):1039-47. PubMed ID: 16038730
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
